[{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pharmaceutical \/ Verastem Oncology"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"VS-6766","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Amgen","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ Amgen"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"The Institute of Cancer Research \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"The Institute of Cancer Research \/ Not Applicable"},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Approved","graph3":"Mirati Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Mirati Therapeutics \/ Verastem Oncology","highestDevelopmentStatusID":"12","companyTruncated":"Mirati Therapeutics \/ Verastem Oncology"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Truist Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Truist Securities","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Truist Securities"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Verastem Oncology \/ RBC Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ RBC Capital Markets"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Guggenheim Securities"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Avutometinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Oberland Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Avutometinib","moa":"||RAF\/MEK","graph1":"Oncology","graph2":"Phase III","graph3":"Verastem Oncology","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Oberland Capital","highestDevelopmentStatusID":"10","companyTruncated":"Verastem Oncology \/ Oberland Capital"}]
Find Clinical Drug Pipeline Developments & Deals for Avutometinib
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
